PEG-MGF
Muscle Building, Repair and Recovery
In short
- MGF with polyethylene glycol attached, which exists solely to solve the parent peptide's minutes-long half-life.
- PEGylation extends circulation time from minutes to a reported several days.
- That change also removes the localised-action rationale — a systemically circulating peptide is not acting at an injection site.
- No human trial exists for either MGF or PEG-MGF.
- Prohibited at all times in sport under WADA class S2.
Structure
A PEGylated 24-amino-acid peptide conjugate. PubChem has no entry under this research-market name, and peptides and proteins of this size are represented by sequence rather than a small-molecule structure diagram.
How it works
PEGylation attaches polyethylene glycol chains to a peptide, increasing hydrodynamic radius and shielding it from proteolytic degradation and renal clearance. It is an established pharmaceutical technique used in several approved biologics.
Applied to MGF, it converts a peptide that survives minutes into one reported to circulate for days. The underlying mechanism — E-domain effects on satellite cell proliferation — is unchanged.
The consequence is that PEG-MGF is a systemic agent. The community rationale for injecting MGF near a trained muscle does not transfer to a version engineered to persist and distribute.
What the research shows
No human study of PEG-MGF has been published.
Rodent work with PEGylated MGF reports improved muscle repair outcomes relative to unmodified peptide, consistent with the pharmacokinetic improvement.
All claims about effects in humans are anecdotal.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Rodent — muscle repair studies with PEGylated MGF | Varies by model; see source | — | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 200–400 µg, two to three times weekly | subcutaneous |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. The extended half-life means dosing errors persist for days rather than clearing in minutes — the same trade-off as CJC-1295 DAC versus its non-DAC form. Less frequent dosing is the reason the PEGylated version exists.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
Subcutaneous injection, two to three times weekly given the extended half-life. Site-local injection has no rationale for a systemically circulating compound.
Side effects
No human safety data for PEG-MGF exists.
A consideration specific to PEGylation: anti-PEG antibodies are a recognised phenomenon with PEGylated biologics, and can cause accelerated clearance or hypersensitivity reactions on repeated exposure. This is documented for approved PEGylated drugs and is a genuine class effect rather than speculation, though it has not been studied for this product.
The proliferative concerns of the IGF-1 family apply, extended over a longer exposure window.
Combinations
Combining with IGF-1 analogues or GH secretagogues compounds growth-factor signalling with no interaction data.
Running both MGF and PEG-MGF is redundant — the same peptide with different pharmacokinetics.
Research status
The PEGylation technique is well established pharmaceutically. Applied to MGF, the literature is preclinical only.
No clinical trial has been registered.
Legal status
Not approved in any jurisdiction. Sold for research use only.
WADA status
PROHIBITED AT ALL TIMES under WADA class S2 — growth hormone secretagogues, their releasing factors and mimetics are explicitly named. Any tested athlete should treat this as an anti-doping violation.
Conclusion
PEG-MGF is a sensible pharmacokinetic fix applied to a compound that was never validated in humans in the first place. Solving the half-life problem does not address whether the peptide does anything useful.
It also quietly abandons the localised-action argument that most MGF marketing rests on.
Sources
Track your own PEG-MGF protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.